The latest cellular or monoclonal-based immunotherapy strategies developed targeting CAIX have surprising preclinical results, particularly against ccRCC, demonstrating the need to conduct clinical studies that explore the potential of CAIX as a therapeutic target. The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.